Clinical effects of adalimumab treatment with concomitant azathioprine in Japanese Crohn’s disease patients

Table 1 Baseline characteristics of all patients who received adalimumab for treatment of Crohn’s disease n (%)

	Adalimumab	Combination	Total
	n = 16	n = 12	n = 28
Gender
Male	13 (81.3)	9 (75.0)	22 (78.6)
Female	3 (18.7)	3 (25.0)	6 (21.4)
Age at presentation1 (yr)	43.1 ± 11.8	31.4 ± 8.3a	38.1 ± 11.8
Disease duration1 (yr)	13.6 ± 11.5	9.3 ± 7.6	11.8 ± 10.1
Location of disease
Isolated ileal	2 (12.5)	1 (8.3)	3 (10.7)
Isolated colonic	4 (25.0)	1 (8.3)	5 (17.9)
leocolonic	10 (62.5)	10 (83.3)	20 (71.4)
Previous resection	10 (62.5)	7 (58.3)	17 (60.7)
Perianal disease	10 (62.5)	6 (50)	16 (57.1)
Current smokers	1 (6.3)	1 (8.3)	2 (7.1)
Previous anti-infliximab treatment	10 (62.5)	7 (58.3)	17 (60.7)
Primary nonresponse	0 (0.0)	1 (8.3)	1 (3.6)
Secondary loss of response	8 (50.0)	6 (50.0)	14 (50.0)
Allergic reaction	1 (6.3)	0 (0.0)	1 (3.6)
Others	1 (6.3)	0 (0.0)	1 (3.6)
CDAI at initiation of adalimumab therapy1	195.4 ± 89.2	152.2 ± 65.8	177.8 ± 82.0
CDAI > 150 at initiation of adalimumab therapy, n	9	7	16
CRP at initiation of adalimumab therapy1	0.72 ± 0.92	0.66 ± 0.73	0.70 ± 0.83

¹Data are expressed as mean ± SD. CDAI: Crohn’s disease activity index.

^aP < 0.05 vs adalimumab.

Table 2 Clinical efficacy of adalimumab therapy

Week	0	2	4	8	24
n	27	25	24	23	19
CDAI	177.8 ± 82.0	124.4 ± 60.2a	120.0 ± 66.8a	123.6 ± 73.5a	135.1 ± 74.4a
Remission	37%	60%	66.70%	69.60%	63.20%

Remission: Crohn’s disease activity index (CDAI ) < 150 points.

^aP < 0.05 vs week 0.